Also found in: Wikipedia.


An oral prostacyclin PGI2 analogue with vasodilator, antiplatelet, and cytoprotective effects, used to manage pulmonary arterial hypertension. Beraprost improves exercise capacity and symptoms in NYHA-functional class-II and -III patients with PAH and, in particular, in those with primary pulmonary hypertension.

Adverse effects
Headache, facial flushing, vasodilation.


Epoprostenol A formulation of prostacyclin in trials for pulmonary vascular disease 2º to treatment with diet drugs
References in periodicals archive ?
Drugs profile discussed in this report include: beraprost sodium SR, LT-0101, MPC-25Osteo, SPI-017, SPI-3608, YLS-1501.
They exceed the improvements reported for other conventional PAD drug therapies including pentoxifylline, cilostazol, dipyridamole, ticlopidine, beraprost, iloprost, naftidrofuryl, and statins, Dr.
Key words: Pulmonary arterial hypertension, prostacylin, epoprostenol, treprostonil, iloprost, beraprost
TSE: 4503) today announced that Toray has obtained marketing approval for its oral PGI2 derivative prolonged release, Careload(R) LA Tablets 60mu/g (generic name: beraprost sodium), to be indicated for pulmonary arterial hypertension (PAH) on October 19,2007.
Beraprost is used in Japan, but has not yet been approved in the United States.
A prostacyclin analog beraprost sodium attenuates radiocontrast media-induced LLC-PK1 cells injury.
Nasdaq: PDII) and United Therapeutics Corporation (Nasdaq: UTHR) today announced that they have signed a five year agreement for PDI to provide a broad range of pre-launch and launch commercialization services for beraprost, a novel compound under development for peripheral vascular disease in the United States.
These findings, while highly significant both statistically and clinically, probably underestimate the true magnitude of treatment benefit in clinical practice because the meta-analysis included negative trials of drugs subsequently denied marketing approval due to lack of efficacy, such as beraprost and terbogrel, as well as studies of approved drugs in non-approved, suboptimal doses.
Other less invasive treatments, such as inhaled iloprost, oral beraprost, and subcutaneous uniprost, are currently being studied in PPH patients.
The eagerly anticipated new agents are iloprost, an inhaled prostacyclin analogue given by nebulizer several times per day; treprostinil (Remodulin), a subcutaneously administered prostacyclin analogue; and Beraprost, an oral prostacydlin analogue.
0 million milestone payment made in connection with the development of a modified release version of the oral prostacyclin analogue, beraprost, under our amended agreement with Toray Industries, Inc.